An FDA advisory panel recommended Emergency Use Authorization for the two-dose Novavax COVID-19 vaccine for people ages 18+. The vaccine is built on a different technology than others currently authorized in the US, and significant delays in manufacturing and authorization have slowed down its entry into the US market. Vaccine expert Dr. Bill Moss returns to the podcast to talk with Lindsay Smith Rogers about Novavax and its potential and what’s behind the delays.
